Characterization of monoclonal antibody recognizing ERCC1 overexpression, a potential biomarker for cisplatin response

被引：0
|
作者：
Oishi, Takayuki [1 ]
Sasaki, Yuka [2 ]
Tong, Ying
Chen Lichao
Onodera, Takae [2 ]
Iwasa, Satoru
Udo, Emiko
Furusato, Bungo
Nakao, Kazuhiko
Yamada, Yasuhide
Hiraoka, Nobuyoshi
Masutani, Mitsuko [2 ]
机构：
[1] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Genom Biomed, Nagasaki, Japan
[2] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol & Genom BioMed, Nagasaki, Japan
来源：
CANCER SCIENCE | 2021年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PJ17-2-3
引用
收藏
页码：915 / 915
页数：1
相关论文
共 50 条
  • [21] Evaluation of ERCC1 Expression for Cisplatin Sensitivity in Human Hepatocellular Carcinoma
    Ueda, Shigeru
    Shirabe, Ken
    Morita, Kazutoyo
    Umeda, Kenji
    Kayashima, Hiroto
    Uchiyama, Hideaki
    Soejima, Yuji
    Taketomi, Akinobu
    Maehara, Yoshihiko
    ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (04) : 1204 - 1211
  • [22] Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours
    Mendoza, J.
    Martinez, J.
    Hernandez, C.
    Perez-Montiel, D.
    Castro, C.
    Fabian-Morales, E.
    Santibanez, M.
    Gonzalez-Barrios, R.
    Diaz-Chavez, J.
    Andonegui, M. A.
    Reynoso, N.
    Onate, L. F.
    Jimenez, M. A.
    Nunez, M.
    Dyer, R.
    Herrera, L. A.
    BRITISH JOURNAL OF CANCER, 2013, 109 (01) : 68 - 75
  • [23] A new step ahead for the consideration of ERCC1 as a candidate biomarker to select NSCLC patients for the treatment of cetuximab in combination with cisplatin
    Olaussen, Ken Andre
    CANCER BIOLOGY & THERAPY, 2009, 8 (20) : 1922 - 1923
  • [24] Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours
    J Mendoza
    J Martínez
    C Hernández
    D Pérez-Montiel
    C Castro
    E Fabián-Morales
    M Santibáñez
    R González-Barrios
    J Díaz-Chávez
    M A Andonegui
    N Reynoso
    L F Oñate
    M A Jiménez
    M Núñez
    R Dyer
    L A Herrera
    British Journal of Cancer, 2013, 109 : 68 - 75
  • [25] SNPs in ERCC1 and drug response to cisplatin in non-small-cell lung cancer patients
    Osawa, Kayo
    PHARMACOGENOMICS, 2011, 12 (04) : 445 - 447
  • [26] XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells:: Role of ERCC1 in homologous recombination repair
    Cummings, Michele
    Higginbottom, Karen
    McGurk, Claire J.
    Wong, Oscar Gee-Wang
    Koberle, Beate
    Oliver, R. Timothy D.
    Masters, John R.
    BIOCHEMICAL PHARMACOLOGY, 2006, 72 (02) : 166 - 175
  • [27] FUNCTIONAL-CHARACTERIZATION OF ERCC1 IN RECOMBINATION AND REPAIR
    ROLIG, RL
    ADAIR, GM
    NAIRN, RS
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1995, : 284 - 284
  • [28] Clinical implication of ERCC1 overexpression in advanced biliary tract adenocarcinoma patients treated with cisplatin-based palliative chemotherapy
    Hwang, In Gyu
    Lee, Gyeong-Won
    Kang, Jung Hun
    Oh, Sung Yong
    Kwon, Hyuk-Chan
    Jun, Hyun Jung
    Lim, Ho Yeong
    Lee, Seungkoo
    Jang, Joung-Soon
    Lee, Sang-Jae
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [29] IS CISPLATIN OTOTOXICITY RELATED WITH GENOTYPE OF DNA REPAIR GENES ERCC1, ERCC2, XRCC1?
    Turan, C.
    Kantar, M.
    Aktan, C.
    Kosova, B.
    Orman, M.
    Kose, T.
    Bilgen, C.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S304 - S304
  • [30] Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas
    Chen, Hua-Yun
    Shao, Cui-Jie
    Chen, Fu-Rong
    Kwan, Aij-Lie
    Chen, Zhong-Ping
    INTERNATIONAL JOURNAL OF CANCER, 2010, 126 (08) : 1944 - 1954
12345